Pfizer Aims to Make Up to 20 Million Doses of COVID-19 Vaccine by End of 2020

Pfizer is hoping to make up to 20 million doses of its COVID-19 vaccine candidate by the end of the year.

The drugmaker is currently testing multiple messenger-RNA vaccine candidates in partnership with BioNTech and plans to move forward with the one that shows the most efficacy.

Nanette Cocero, global president of Pfizer Vaccines, said that the company is investing in raw materials to scale up its manufacturing capacity while trials are underway. She said the company aims to produce 10 million to 20 million doses for emergency use settings by the end of the year.

BioNTech has dosed the first cohort of patients in a phase 1/2 trial of the potential vaccine in Germany. Pfizer said it will begin trials in the U.S. as early as this week (DID, April 30). — Jordan Williams